Shuman, Glenn & Stecker Investigates Vanda Pharmaceuticals Inc.
Shuman, Glenn & Stecker Investigates Vanda Pharmaceuticals Inc.
Shuman, Glenn & Stecker announces that it is investigating potential claims against certain officers and directors of Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (Nasdaq: VNDA). Vanda is a pharmaceutical development company.
The Firm’s investigation relates to allegations raised in a securities class action against Vanda and certain of its senior officers in the U.S. District Court for the Eastern District of New York. The complaint alleges that between 2015 and 2019, Vanda was involved in a fraudulent scheme that included violations of federal Medicare, Medicaid, and Tricare programs to promote its drugs Fanapt and Hetlioz for "off-label". The complaint further alleges that Vanda's executives and officers knew about the prohibited promotional strategies and actively participated in the fraudulent activity. When the truth was revealed, Vanda's stock declined over 5%.
On March 10, 2021, U.S. District Judge Frederic Block denied Vanda and its CEO’s motion to dismiss the securities class action against, paving the way for the case to proceed towards trial.
If you currently own Vanda common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip Shuman toll free at (866) 569-4531 or email Mr. Shuman at kip@shumanlawfirm.com.
Shuman, Glenn & Stecker represents investors throughout the nation, concentrating its practice in stockholder litigation.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210318005964/en/
Contacts
SHUMAN, GLENN & STECKER
Kip B. Shuman, Esq.
100 Pine Street, Suite 1250
San Francisco, CA 94111
Tel: 866.569.4531
Fax: 303.536.7849
Email: kip@shumanlawfirm.com
Web: www.shumanlawfirm.com
Shuman, Glenn & Stecker announces that it is investigating potential claims against certain officers and directors of Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (Nasdaq: VNDA). Vanda is a pharmaceutical development company.
SHuman，Glenn&Stecker宣佈，它正在調查針對某些高管和董事的潛在索賠萬達製藥公司。(“萬達”或“公司”)(納斯達克市場代碼：VNDA)。萬達是一家制藥開發公司。
The Firm’s investigation relates to allegations raised in a securities class action against Vanda and certain of its senior officers in the U.S. District Court for the Eastern District of New York. The complaint alleges that between 2015 and 2019, Vanda was involved in a fraudulent scheme that included violations of federal Medicare, Medicaid, and Tricare programs to promote its drugs Fanapt and Hetlioz for "off-label". The complaint further alleges that Vanda's executives and officers knew about the prohibited promotional strategies and actively participated in the fraudulent activity. When the truth was revealed, Vanda's stock declined over 5%.
該公司的調查涉及在美國地區法院對萬達及其某些高級官員提起的證券集體訴訟中提出的指控東方紐約特區。起訴書稱，2015年至2019年期間，萬達參與了一項欺詐性計劃，其中包括違反聯邦醫療保險(Medicare)、醫療補助(Medicaid)和Tricare計劃，宣傳其藥物Fanapt和Hetlioz的“標籤外”。起訴書進一步指控，萬達的高管和管理人員知道被禁止的促銷策略，並積极參與欺詐活動。當真相被披露時，萬達的股價下跌了5%以上。
On March 10, 2021, U.S. District Judge Frederic Block denied Vanda and its CEO’s motion to dismiss the securities class action against, paving the way for the case to proceed towards trial.
2021年3月10日，美國地區法官弗雷德裏克·布洛克(Frederic Block)駁回了萬達及其首席執行官提出的駁回針對證券公司的集體訴訟的動議，為該案進入審判鋪平了道路。
If you currently own Vanda common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip Shuman toll free at (866) 569-4531 or email Mr. Shuman at kip@shumanlawfirm.com.
如果您目前持有Vanda普通股，並有興趣討論您的權利，或有關於此次調查的信息，請撥打免費電話(866)569-4531與Kip SHuman聯繫，或發送電子郵件至kip@shumanlawfir.com聯繫舒曼先生。
Shuman, Glenn & Stecker represents investors throughout the nation, concentrating its practice in stockholder litigation.
SHuman，Glenn&Stecker代表全國的投資者，專注於股東訴訟。
View source version on businesswire.com:https://www.businesswire.com/news/home/20210318005964/en/
查看businesswire.com:https://www.businesswire.com/news/home/20210318005964/en/上的源代碼版本
Contacts
聯繫人
SHUMAN, GLENN & STECKER
舒曼、格倫和斯特克
Kip B. Shuman, Esq.
基普·B·舒曼(Kip B.SHuman)，Esq.
100 Pine Street, Suite 1250
松樹街100號，1250套房
San Francisco, CA 94111
加利福尼亞州舊金山，郵編：94111
Tel: 866.569.4531
電話：866.569.4531
Fax: 303.536.7849
傳真：303.536.7849
Email: kip@shumanlawfirm.com
電子郵件：kip@shumanlawfir.com
Web: www.shumanlawfirm.com
網址：www.shumanlawfir.com
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧